Signaling through the receptor for epidermal growth factor receptor (EGFR) is frequently
deregulated in solid tumors. Erlotinib (Tarceva, OSI-774, OSI Pharmaceuticals, Inc., Melville …

Purpose: Preclinical modeling in non–small cell lung cancer (NSCLC) showed that
stimulation with hepatocyte growth factor (HGF), the ligand for MET, could reverse the …

Our objective was the preclinical assessment of the pharmacokinetics, monotherapy and
combined antitumor activity of the epidermal growth factor receptor (HER1/EGFR) tyrosine …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, with no
effective treatment for most individuals who succumb to this neoplasm. We report that …

We investigated whether EGFRvIII contributes to tumorigenicity and resistance to 5-FU in
HCC cell lines. Our results show that several HCC cell lines have EGFRvIII expression …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Purpose We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods Patients were assigned to one of …

Background: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy.
However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in …

The epidermal growth factor receptor (EGFR) is considered an important therapeutic target
in pancreatic cancer, but it is currently impossible to identify those patients who are most …

Methods Several different human HCC cell lines were used to test the growth-inhibiting
effects and cell toxicity of silibinin both alone and in combination with either gefitinib or …